Patent · US Expired

Use of a direct-acting thrombin inhibitor for the manufacture of a medicinal product having thrombolytic activity

US5583113A · kind A · utility

4Cited by

3References

2Claims

0Family size

Assignee

Synthelabo · FR

Inventors

Christopher Berry · Manlius, US
Patrice Ferrari · Bois-d'Arcy, FR

Key dates

Filing date	Feb 13, 1995
Grant date	Dec 10, 1996
Priority date	—
Expiry date	Feb 13, 2015

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P7/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method for inducing thrombolysis, which method comprises administering to a patient a thrombolytically effective amount of a thrombin inhibitor which acts at the active site of thrombin, in the absence of exogenous plasminogen activator. The inhibitor is preferably argatroban, D-Phe-Pro-Arg-chloromethyl ketone, or Ac-(D-Phe)-Pro-boro-Arg-OH.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.